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The development of novel protein-targeted MRI contrast agents crucially depends on the ability to
derivatise suitable targeting moieties with a high payload of relaxation enhancer (e.g., gadolinium(III)
complexes such as Gd-DOTA), without losing aﬃnity for the target proteins. Here, we report robust
synthetic procedures for the preparation of trivalent Gd-DOTA reagents with various chemical handles
for site-speciﬁc modiﬁcation of biomolecules. The reagents were shown to successfully label proteins
through isothiocyanate ligation or through site-speciﬁc thiol–maleimide ligation and strain-promoted
azide–alkyne cycloaddition.Introduction
Magnetic resonance imaging (MRI) is widely used for non-
invasive imaging of physiological processes in both clinical
medicine and pre-clinical research. MRI is especially advanta-
geous because, in comparison to other imaging modalities, it
oﬀers the opportunity to image deep into tissue without the
need for ionising radiation, and because it provides 3D images
with sub-millimeter spatial resolution.1–3 Most MRI methods
rely on 1H NMR signals of water protons, so signals depend on
their concentrations and relaxation times (T1 and T2). Chemical
contrast agents, for example those based on gadolinium(III) or
manganese(II) complexes or on iron oxide nanoparticles, can
signicantly enhance the sensitivity of MRI, and have already
had major impact on (pre)clinical imaging. All clinically
approved MRI contrast agents that are currently in use are
based on the paramagnetic Gd3+ ion,4 which can shorten the
spin–lattice relaxation time (T1) of water in its coordination
spheres. Eﬃcient Gd3+-based MRI contrast agents undergo
rapid exchange of inner-sphere water molecules with bulk
water, resulting in signicant enhancement of MR contrast by
low micromolar concentrations of Gd3+.1–3S2 9JT, UK. E-mail: r.bon@leeds.ac.uk
logy, University of Leeds, UK
niversity of Leeds, UK
bolic Medicine, University of Leeds, UK
Centre, University of Leeds, UK
(ESI) available: Synthetic details for
ds for bioconjugation reactions; copies
pounds prepared according to new
0Targeted MRI contrast agents consist of a targeting moiety
and one or more gadolinium complexes. The targeting moiety is
usually a small molecule or peptide. These reagents can be used
to localise specic proteins – typically proteins present in the
blood or extracellular matrix, or extracellular domains of
membrane proteins – in vivo with high spatial resolution.
Examples are MRI contrast agents targeted to serum albumin,
collagen, brin,2,3 and various abundant receptors (e.g.,
progesterone, folate, dopamine glutamate).1 In addition,
a contrast agent based on CTB (cholera toxin subunit B) has
been used to successfully image neuronal connections in vivo.5
The development of protein-targeted MRI contrast agents
crucially depends on the availability of suitable protein-
targeting moieties that can be labelled eﬃciently with
(multiple) gadolinium complexes while preserving: (1) aﬃnity
of the targeting moiety for its protein target; (2) strong binding
of toxic Gd3+ to its chelating ligand; (3) relaxivity of the gadoli-
nium complex; (4) rapid tissue penetration/target binding and
clearance of unbound reagents; and (5) clearance of all reagent
from the body before metabolism-related release of Gd3+.
For many proteins, no suitable small molecule ligands are
available, and the use of biomolecules as targeting moieties
would be desirable. For example, antibody- and aﬃbody-based
MRI contrast agents have been developed that enable the tar-
geted imaging of EGFR and Her-2,6 including a two-component
approach based on a biotinylated antibody and Gd-DTPA-
labelled avidin to increase the gadolinium payload (with
a detection limit of ca. 106 receptors per cell).7 Aﬃbodies and
other antibody mimetics have signicant advantages over
antibodies as targeting moieties: they are smaller, causing rapid
tissue penetration and blood clearance; they can be selected
rapidly in vitro against a wide range of biomolecules; they areThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineeasier to produce in homogeneous batches that are devoid of
post-translational modications; and they can be labelled site-
specically with suitable chemicals.
Macrocyclic ligands such as DOTA and DO3A are metaboli-
cally more stable than linear ones such as DTPA, and they bind
Gd3+ much more tightly (pKD ¼ 28 for DOTA vs. 22 for DTPA),8
minimising potential toxicity issues. DOTA can be linked to
targeting moieties through amide bond formation with one (or
more) of its carboxylic acids. However, the change of a coordi-
nating carboxylate to an amide slightly reduces the binding
constant of the Gd-DOTA complex. More importantly, this
substitution signicantly slows the water exchange rate of the
complex (a limiting factor when imaging slow-tumbling mole-
cules).1,3 Our aim was to generate a toolbox of trivalent Gd-
DOTA reagents that already contain Gd3+ and can be used to
selectively label any targeting moiety (i.e. small molecules,
peptides and biomolecules) in one simple step. The trivalent
Gd-DOTA reagents were based on DOTA-GA in combination
with a diethylenetriamine linker (Fig. 1). DOTA-GA contains
a glutamic acid side chain that allows chemical modication
without negatively aﬀecting the water exchange rate of the Gd-
DOTA complex. In addition, the limited rotational freedom of
the short triamine linker would ensure minimal loss of relax-
ivity through rotational motion (a limiting factor when using
clinically prevalent mid-range scanners).1,3
One trivalent complex [Gd-DOTA]3-X (Fig. 1, X ¼ NCS;
compound 14) has previously appeared in the patent literature.9
However, DOTA chemistry is notoriously sensitive to impurities
and, in our experience, the details disclosed in this patent are
insuﬃcient to allow straight-forward preparation of trivalent
Gd-DOTA reagents. Here, we provide detailed (optimised)
procedures for the synthesis and purication of one known and
two new trivalent Gd-DOTA reagents [Gd-DOTA]3-X. In addition,
we report on bioconjugation studies for the modication of
proteins such as antibody mimetics.Fig. 1 Generic structure of trivalent Gd-DOTA reagents [Gd-DOTA]3-
X described in this study (X ¼ reactive handle for chemoselective
conjugation to biomolecules).
This journal is © The Royal Society of Chemistry 2015Results and discussion
Synthesis of (R)-tBu4-DOTA-GA
DOTA-based building block (R)-tBu4-DOTA-GA (6) was syn-
thesised through adaptation of a literature procedure reported to
give 6 in high purity and >97% enantiomeric excess (Scheme 1).10
L-Glutamic acid was converted to lactone 1 through diazotisation
followed by tert-butyl ester formation, in moderate yield (over 3
steps, aer crystallisation).11 Lactone ring opening with 1 equiv-
alent of KOH, followed by benzylation of the intermediate
potassium carboxylate, gave alcohol 2, which was mesylated in
good yield. Alcohol 2 was easy to store. Therefore, mesylate 3 was
always prepared freshly before use.
Levy et al. synthesised benzyl-protected DOTA-GA 5 by mono-
alkylation of cyclen with mesylate 3 followed by triple alkylation
with tert-butylbromoacetate. Their procedure required 2 equiva-
lents of cyclen (an expensive building) in the rst step to avoid
over-alkylation, and removal of excess cyclen aer the reaction
was essential to avoid problems in subsequent steps.10 In
contrast, we isolated tri-functionalised cyclen 4 as its pure HBr
salt by crystallisation from chloroform/diethyl ether.12 Alkylation
of 4 with 1.2 equivalents of 3 under basic conditions aﬀorded 5.
Benzyl ester 5 was highly sensitive to trans-esterication
under basic conditions. Even aer ltration of the crude reac-
tionmixture, suﬃcient potassium carbonate was present to give
the corresponding methyl ester upon addition of methanol.13
Therefore, 5 was puried by automated reverse phase (RP; C18)
chromatography before hydrogenolysis to aﬀord (R)-tBu4-DOTA-
GA (6). We also noticed that amide bond formations with 6 areScheme 1 Synthesis of (R)-tBu4-DOTA-GA (6). Reagents and condi-
tions: (a) NaNO2, aq. HCl, dioxane, 0 C/ rt, 1.5 h; (b) (COCl)2, DMF,
DCM, 0 C/ rt, 2 h; (c) tBuOH, 2,6-lutidine, DCM, 0 C/ rt, 16 h, 38%
over 3 steps; (d) 1 M KOH (1 equiv.), THF, rt, 2 h; (e) benzyl bromide,
DMF, 8 h, 55% over 2 steps; (f) MsCl, DIPEA, DCM, 0 C/ rt, 30 min,
71%; (g) tert-butylbromoacetate, DMA, NaOAc, 0 C/ rt, 16 h, 70%;
(h) 3, K2CO3, MeCN, rt/ 60 C, 16 h, 70%; (i) H2, 5% Pd/C, MeOH, rt, 16
h, 80%.
RSC Adv., 2015, 5, 96194–96200 | 96195
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View Article Onlinevery sensitive to residual alcohol or water; rapid hydrolysis/
methanolysis of activated esters of 6 is consistent with the
sensitivity of 5 to trans-esterication. Therefore, 6 (1.35 g) was
puried by automated RP (C18) chromatography and subse-
quent lyophilisation. The use of an acid-free eluent during this
purication was crucial to avoid formation of salts, and for
consistent results with subsequent amide bond formations. The
ee of 6 was >97%, as determined by NMR analysis upon
formation of amides with either enantiomer of a-methyl-
benzylamine, according to reported procedures.10Synthesis of trivalent Gd-DOTA reagents
Trivalent linker 9 was prepared in 2 steps from L-nitro-
phenylalaninemethyl ester 7 according to a literature procedure
(Scheme 2).14 Triamine 9 was isolated as its triple HCl salt,
which is hygroscopic and needs to be stored under an inert
atmosphere for consistent results in subsequent acylation with
(R)-tBu4-DOTA-GA (6). Aer extensive optimisation of reactionScheme 2 Synthesis of the trivalent Gd-DOTA reagents [Gd-DOTA]3-
maleimide (13), [Gd-DOTA]3-ITC (14), and [Gd-DOTA]3-N3 (15) via
[Gd-DOTA]3-NH2 (12). Reagents and conditions: (a) ethylene diamine,
rt, 16 h, 97%; (b) BH3 in THF, 0 C/ reﬂux, 19 h, 43% (isolated as triple
HCl salt); (c) 6, HATU, DIPEA, DMF, 0 C/ rt, 16 h, 88%; (d) H2, 10% Pd/
C, MeOH, 40 C, 16 h, 93%; (e) TFA, TES, MsOH, 0 C, 4.5 h; (f) GdCl3,
aq. NaOH (pH 6.5), rt / 50 C, 16 h, 75% over 2 steps; (g) 2-mal-
eimidoacetic acid-OSu, HEPES buﬀer pH 7.3, DMSO, 6 h, 40%; (h)
CSCl2, CHCl3 : H2O (1 : 1), rt, 16 h, 70%; (i) 3-azidopropylamine,
carbonate buﬀer pH 9.4, DMSO, rt, 2 h, 76%.
96196 | RSC Adv., 2015, 5, 96194–96200conditions, triple acylation of triamine 9with 6 using HATU and
DIPEA aﬀorded [(R)-tBu4-DOTA]3-NO2 (10) in excellent yield. In
contrast to reported procedures, only a small excess of 6 (1.1
equiv. per acylation) was required. The best conversion was seen
with freshly freeze-dried 6 (puried as described above) and
anhydrous DIPEA. Consistent with the patent literature, puri-
cation of 10 by ash chromatography was only partially
successful, and gave low yield of pure material.9 However,
straight-forward size exclusion chromatography (Sephadex LH-
20), followed by lyophilisation, gave 10 in high yield.
Hydrogenation of the nitro group of 10 gave aniline [(R)-tBu4-
DOTA]3-NH2 (11) as a pure compound, which was converted
into [Gd-DOTA]3-NH2 (12) in two steps. The use of meth-
anesulfonic acid, in addition to TFA and the cation scavenger
triethylsilane, was essential for the deprotection of all 12 tert-
butyl esters of 11.15 The reaction worked best when kept at or
just above 0 C; signicant decomposition and reduced yields
were observed if the reaction mixture was allowed to warm up.
Therefore, the deprotected intermediate (as its methanesulfo-
nate salt) was separated from the deprotection cocktail by
precipitation upon addition of cold diethyl ether. The resulting
trivalent DOTA ligand was then directly charged with Gd3+ to
aﬀord trivalent DOTA chelate [Gd-DOTA]3-NH2 (12). The crude
product 12 was puried by size exclusion chromatography to
remove excess salts. Formation of the paramagnetic complex 12
was conrmed by high resolution ESI-MS.15 Puried aniline 12
was prepared in batches of ca. 350–400 mg, and could be stored
at 20 C for >1 year without signs of decomposition.
Next, aniline 12 was modied to install reactive handles for
the labelling of targeting moieties, including peptides and
biomolecules. Modications of 12 were performed on small
scales (6–50mg) to producematerial for bioconjugation studies.
Acylation with the N-hydroxylsuccinimide ester of 2-mal-
eimidoacetic acid (2-maleimidoacetic acid-OSu),16 aﬀorded [Gd-
DOTA]3-maleimide (13) suitable for selective modications of
thiols (e.g., cysteines). Treatment of 12 with thiophosgene gave
[Gd-DOTA]3-ITC (14) suitable for reactions with nucleophilic
amines (e.g., lysines). Isothiocyanate 14 could also be converted
into the azide [Gd-DOTA]3-N3 (15), suitable for, for example,
copper-catalysed azide–alkyne cycloadditions (CuAAC) or strain-
promoted azide–alkyne cycloadditions (SPAAC). 2-Maleimido-
acetic acid-OSu and 3-azidopropylamine were separated from
trivalent Gd-DOTA reagents 13 and 15, respectively, using size
exclusion chromatography before bioconjugation reactions;
isothiocyanate 14 did not require purication.Bioconjugation studies with trivalent Gd-DOTA reagents
Next, the suitability of trivalent Gd-DOTA reagents 13, 14 and 15
for protein modication was investigated. Initially, bio-
conjugation experiments were performed with lysozyme. Incu-
bation of lysozyme (71 mM in 0.1 M sodium carbonate) with
three equivalents of 14 resulted in rapid bioconjugation (Fig. 2a
and b). SDS-PAGE analysis showed mainly single and double
labelling of lysozyme, and some triple labelling (Fig. 2a, lane 1).
The identity of the singly- and doubly-labelled lysozyme was
conrmed by ESI-MS (Fig. 2b and the ESI†).17 Preincubation ofThis journal is © The Royal Society of Chemistry 2015
Fig. 2 Modiﬁcation of biomolecules with trivalent Gd-DOTA reagents.
(a and b) Reaction of lysozyme (71 mM in 0.1 M Na2CO3) with ITC 14 (3
equiv.; 18 h) resulted in single, double and triple labelling, according to
SDS-PAGE (a) and high resolution ESI-MS ((b); deconvoluted spectrum
shown) analysis. In (a) lane 1: lysozyme; lane 2: lysozyme after reaction
with ITC 14; lane 3: ITC 14 pre-incubated with carbonate buﬀer for 45
min before reaction with lysozyme. (c and d) Reaction of Adhiron15C
(84 mM in phosphate buﬀer pH 7.4) with maleimide 13 (40 equiv.; 6 h)
resulted in single labelling only, according to SDS-PAGE (c) and high
resolution ESI-MS ((d); deconvoluted spectrum shown) analysis. In (c)
lane 1: Adhiron15C the minor band at higher mass represents a small
amount of Adhiron15C dimer (disulﬁde); lane 2: Adhiron15C upon
reaction with maleimide 13. (e and f) Two-step labelling of Adhiron15C
(50 mM in phosphate buﬀer pH 7.4) with azide 15 (2 equiv.; 6 h) resulted
in rapid strain-promoted azide–alkyne cycloaddition according to
SDS-PAGE (e) and high resolution ESI-MS ((f); deconvoluted spectrum
shown) analysis. In (e) lane 1: Adhiron15C upon reaction with diben-
zocyclo-octyne maleimide (DBCO-Mal; 20 equiv.; 6 h); lane 2:
Adhiron15C-DBCO upon reaction with azide 15 (2 equiv.; 6 h).
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View Article Online14 in 0.1 M sodium carbonate for 45 minutes before addition of
lysozyme resulted in identical labelling patterns (Fig. 2a, lane 2),
which indicates that 14 is relatively stable in basic aqueous
solution. In addition, 14 could be stored as a powder at 20 C
for >1 year without aﬀecting its reactivity.
Our ongoing research focuses on the use of functionalised
Adhirons for targeted imaging. Adhirons (also known as Aﬃm-
ers) are a novel class of small (ca. 12 kDa) antibody mimetics thatThis journal is © The Royal Society of Chemistry 2015can be selected rapidly in vitro against a range of targets using
phage display protocols.18 Adhirons have excellent binding
aﬃnity and specicity, high thermal stability, low production
costs and no disulde bonds. Compared to antibodies, their
much smaller size would facilitate more rapid tissue penetration
and blood clearance, which is advantageous for in vivo imaging.
In addition, the ease of engineering of site-specicmodications,
including single or multiple cysteines, makes Adhirons well-
suited for site-specic chemical labelling. To test the site-
specic modication of Adhirons with trivalent Gd-DOTA
reagents, bioconjugation reactions were performed with Adhir-
on15C, which contains a single cysteine on its C-terminus
(pointing away from the binding loops) (Fig. 2c–f). Adhiron15C
contains a C-terminal His tag and was puried by Ni nitrilotri-
acetic acid (NTA) aﬃnity chromatography. Initially, labelling with
maleimide 13 was performed directly in the elution buﬀer, at
a protein concentration of 84 mM. SDS-PAGE analysis showed
formation of a single labelling product even in the presence of 40
equiv. of 13 (Fig. 2c) and high resolution ESI-MS conrmed the
identity of Adhiron15C-[Gd-DOTA]3 (Fig. 2d).
Although the labelling of Adhiron15Cwithmaleimide 13was
successful, a large excess of this precious reagent was needed.
To check if ineﬃcient labelling was caused by imidazole and/or
tris(2-carboxyethyl)phosphine (TCEP) present in the Adhiron
elution buﬀer, ligation reactions were also attempted aer
purication of Adhiron15C by dialysis into labelling buﬀer (PBS
containing 10% glycerol and 0.05% Tween-20; pH 7.4) and/or
gel ltration. However, this did not signicantly improve the
labelling reaction, and neither did the use of polymer-
supported TCEP (instead of TCEP solution) to reduce disulde
bonds of Adhiron dimers before labelling. Therefore, a more
eﬃcient 2-step protocol for Adhiron labelling based on SPAAC19
was developed. Treatment of Adhiron15C (50 mM in labelling
buﬀer) with the commercially available linker dibenzocyclo-
octyne maleimide (DBCO-Mal; see the ESI† for structure; 20
equiv.) gave Adhiron15C-DBCO (Fig. 2f).
Aer buﬀer exchange (PD-10 column) and concentration,
Adhiron15C-DBCO (89 mM in labelling buﬀer) was treated with
azide 15 (2 equiv.), leading to rapid formation of Adhiron15C-
DBCO-[Gd-DOTA]3 by SPAAC (Fig. 2e and f). Although conver-
sion was still not complete (most likely because of the sluggish
maleimide ligation to form Adhiron15C-DBCO), this procedure
gave similar conversion to direct ligation with maleimide 13,
but is signicantly more eﬃcient in terms of the required
amount of trivalent Gd-DOTA reagent.
Conclusions
Trivalent Gd-DOTA reagents have been developed for the site-
specic functionalisation of (bio)molecules bearing amines,
thiols, and/or (strained) alkynes. Detailed synthetic procedures
have been reported, including recommendations regarding puri-
cation and storage to assure high-yielding reactions with sensi-
tive intermediates. Procedures for the (site-specic) modication
of diﬀerent proteins were developed. Our reagents allow a range
of chemoselective ligation reactions with targeting moieties,
including biomolecules. Therefore, they may contribute to theRSC Adv., 2015, 5, 96194–96200 | 96197
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
3/
12
/2
01
5 
12
:1
3:
44
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinedevelopment of novel MRI contrast agents targeted to proteins for
which no suitable and/or easy-to-functionalise small molecule- or
peptide-based binders are available, but for which phage display
protocol can deliver antibody mimetics with high aﬃnity and
selectivity. In addition, our reagents could triple the gadolinium
payload of previously described CTB-based neuronal tracers.5 We
are currently using our reagents to optimise the gadolinium
payload on Adhiron-based contrast agents, for example through
multiple labelling or the inclusion of a polyvalent scaﬀold.7
Experimental
Synthetic procedures
The following compounds were prepared using literature
methods and full reaction details can be found in the ESI:† 1,10
2,10 3,10 4,12 8,14 9,14 2-maleimidoacetic acid (S1)16 and 2-mal-
eimidoacetic acid-OSu (S2).16
(R)-tBu4-DOTA-GA benzyl ester 5. A solution of benzyl 5-(tert-
butoxy)-4-(methanesulfonyloxy)-5-oxopentanoate 3 (1.85 g, 4.9
mmol) in MeCN (20 mL) was added dropwise to a suspension of
trialkylated cyclen 4 (2.4 g, 4.1 mmol) and potassium carbonate
(1.7 g, 12.4 mmol) in MeCN (15 mL) at room temperature. The
reaction mixture was stirred at 60 C overnight. Once the reac-
tion was complete according to LCMS, the reaction mixture was
cooled, ltered over Celite, and concentrated in vacuo. The
residue was taken up in DCM (20 mL), ltered over Celite, and
concentrated in vacuo. The resulting orange oil was dissolved in
MeCN : H2O (20 : 80) and puried by automated RP (C18)
chromatography using gradient elution (MeCN–H2O–HCOOH,
15 : 90 : 0.1 to 85 : 10 : 0.1). The eluate was concentrated in
vacuo to give an aqueous emulsion (6–10 mL) which was
lyophilised to give the title compound (as its double formic acid
salt) as a viscous amber oil (2.7 g, 70%). nmax cm
1 2979 and
1725; dH (500 MHz; CDCl3), 9.65–10.15 (br s, 2H), 8.48 (s, 2H),
7.30–7.38 (m, 5H), 5.11 (s, 2H), 3.71–3.79 (m, 4H), 3.44 (s, 2H),
3.34 (dd, J 4.2, 10.1, 1H), 3.12–3.22 (m, 8H), 2.94–3.00 (m, 4H),
2.85–2.94 (m, 4H), 2.38–2.52 (m, 2H), 2.03–2.11 (m, 1H), 1.86–
1.94 (m, 1H), 1.44–1.47 (three s, 36H); dC (125 MHz; CDCl3),
172.5, 171.0, 169.4, 168.5, 166.0, 135.7, 128.6, 128.4, 128.3, 82.8,
82.4, 82.3, 66.4, 63.1, 56.4, 55.2, 52.9, 52.5, 49.9, 46.8, 30.9, 28.2,
28.1, 23.7;m/zHRMS (ESI) calcd for C42H71N4O10: 791.5165 [M +
H]+, found 791.5174.
(R)-tBu4-DOTA-GA 6. 5% Pd/C (250 mg) was added to a stir-
red solution of 5 (1.9 g, 2.4 mmol) in MeOH (40 mL) under an
atmosphere of nitrogen. The reaction was then placed under an
atmosphere of hydrogen (balloon; three cycles of evacuation
(aspirator) and back-lling) and stirred overnight. Once the
reaction was complete according to LCMS, the reaction mixture
was ltered over Celite and the solvent removed in vacuo. The
crude material was dissolved in MeCN : H2O (20 : 80) and
puried by automated RP (C18) chromatography using gradient
elution (MeCN–H2O, 10 : 90 to 90 : 10). The eluate was
concentrated in vacuo to give an aqueous solution (5–10 mL)
which was lyophilised to give the title compound as a colourless
amorphous solid (1.35 g, 80%). nmax cm
1 3426, 3096, 2979,
1954 and 1720; dH (500 MHz; CDCl3) 6.62–6.97 (bs, 1H), 3.59–
3.67 (m, 4H), 3.55 (t, J 6.9, 1H), 3.48 (s, 2H), 2.94–3.19 (m, 14H),96198 | RSC Adv., 2015, 5, 96194–962002.84–2.92 (m, 2H), 2.51–2.59 (m, 1H), 2.39–2.48 (m, 1H), 1.98–
2.06 (m, 1H), 1.87–1.96 (m, 1H), 1.40–1.48 (three s, 36H); dC (125
MHz; CDCl3) 176.1, 171.4, 170.8, 170.3, 81.6, 81.3, 81.1, 63.6,
56.1, 55.7, 52.0, 51.7, 49.4, 33.1, 28.3, 28.2, 27.93, 27.87, 25.3;m/
z HRMS (ESI) calcd for C35H65N4O10: 701.4695 [M + H]
+, found
701.4702.
[(R)-tBu4-DOTA]3-NO2 10. DIPEA (526 mL, 3.20 mmol) was
added to a cooled (0 C), stirred solution of HATU (546 mg, 1.41
mmol), 6 (400 mg, 1.14 mmol), and 2-amino-3-(400-nitrophenyl)
propyl (20-aminoethyl)amine trihydrochloride 9 (55 mg, 0.32
mmol) in DMF (6 mL). The reaction mixture was stirred at 0 C
for 30 minutes, then allowed to warm to room temperature and
stirred overnight. Once the reaction was complete according to
LCMS, the reaction mixture was concentrated in vacuo and re-
dissolved in MeOH, then puried by size exclusion chroma-
tography (Sephadex LH-20; elution with MeOH). The puried
product was concentrated in vacuo. The residue was taken up in
H2O, then lyophilised to give the title compound as a colourless
amorphous solid (650 mg, 88%). dH (500 MHz; CDCl3) 8.06–8.12
(m, 2H), 7.49–7.60 (m, 2H), 4.34–4.58 (m, 1H), 2.80–3.92 (m,
77H), 2.15–2.61 (m, 6H), 1.90–2.13 (m, 6H), 1.37–1.51 (m, 108H);
m/z HRMS (ESI) calcd for C116H207N16O29: 763.1744 [M + 3H]
3+,
found 763.1739.
[(R)-tBu4-DOTA]3-NH2 11. 10% Pd/C (180 mg) suspended in
MeOH (1mL) was added to a solution of 10 (410 mg, 0.18 mmol)
in MeOH (5 mL) under an atmosphere of nitrogen. The reaction
was then placed under an atmosphere of hydrogen (balloon;
three cycles of evacuation (aspirator) and back-lling) and
stirred at 40 C until complete according to LCMS (16 h). The
reaction mixture was cooled to room temperature, ltered over
Celite, and concentrated in vacuo to give the title compound as
a colourless amorphous solid (380 mg, 93%). dH (500 MHz;
CDCl3) 6.91–7.02 (m, 2H), 6.53–6.62 (m, 2H), 4.31–4.21 (m, 1H),
1.63–3.92 (m, 89H), 1.39–1.50 (m, 108H); m/z (LC-ESI-MS) calcd
for C116H207N16O27: 752.8 [M + 3H]
3+, found 753.3 (pattern for
sequential deprotection of tBu groups observed).
[Gd-DOTA]3-NH2 12.15 Pre-cooled (0 C) TFA (3.5 mL) and TES
(1.2 mL, 30 mmol) were added to solid 11 (500 mg, 0.22 mmol),
aer which vigorous bubbling was observed. The reaction
temperature was maintained at 0 C for 20 minutes. Then,
MsOH (227 mL) was added and the reaction mixture was stirred
for 4 h at 0 C. Once the reaction was complete according to
LCMS, the reaction mixture was poured into cold ether (40 mL)
in a falcon tube. The resulting precipitate was stored in the
fridge for 1 hour then centrifuged (1800  g, 5 min). The
supernatant was decanted oﬀ and the residue dissolved in
water, then lyophilised to give a colourless amorphous solid
(510 mg). This solid was dissolved in H2O (4 mL) and the pH
adjusted to 6.5 with 2 N NaOH. To this solution was added
GdCl3$6H2O (3  90 mg, 0.73 mmol) successively in 3 portions;
aer each addition the pH was monitored until no further
change was observed (ca. 20 min) and the pH readjusted to 6.5
with 2 N NaOH before the next addition. Aer the nal addition,
the pH was again adjusted to 6.5 and the cloudy pink solution
was heated to 50 C overnight. Once complete according to
LCMS the mixture was ltered over Celite and lyophilised. The
crude product was puried by size exclusion chromatographyThis journal is © The Royal Society of Chemistry 2015
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View Article Online(Sephadex LH-20; elution with H2O). The puried product was
lyophilised to give the title compound as a pale pink amorphous
solid (360 mg, 75% over 2 steps). m/z HRMS (ESI, negative
mode) calcd for C68H98Gd3N16O27: 681.1514 M
3, found
681.1494 (complex pattern due to Gd isotopes; the predicted
and observed isotopic distributions were identical, see ESI†).
[Gd-DOTA]3-maleimide 13. To a solution of 12 (50 mg, 0.024
mmol) inHEPES buﬀer (300mM, pH 7.3, 300 mL) andDMSO (200
mL), a solution of 2-maleimidoacetic acid-OSu (18 mg, 0.072
mmol) in DMSO (100 mL) was added. Because a precipitate
formed, the reactionmixture was centrifuged (17 000 g, 1 min),
and the supernatant was removed and retained before the pellet
was redissolved in DMSO (100 mL) and added back to the
supernatant. The reaction was spun (Stuart rotator) at room
temperature for 4 h before a further aliquot of 2-maleimidoacetic
acid-OSu (18 mg, 0.072 mmol) in DMSO (200 mL) was added. The
reaction mixture was spun for a further 2 h, then loaded onto
a size exclusion chromatography (LH20) column, and the product
was eluted with H2O. The eluted product was lyophilised to give
the title compound as an oﬀ-white solid (20 mg, 40%, some
starting material 12 present according to LCMS), which was used
immediately for bioconjugation reactions. m/z HRMS (ESI,
negative mode) calcd for C74H101Gd3N17O30: 726.4889 M
3,
found 726.4918 (complex pattern due to Gd isotopes; the pre-
dicted and observed isotopic distributions were identical, see
ESI†).
[Gd-DOTA]3-ITC 14. Thiophosgene (3.3 mL, 0.013 mmol) was
added to a biphasic solution of 12 (50 mg, 0.024 mmol) in chlo-
roform–H2O (50 : 50, 1 mL), and the reaction mixture was stirred
vigorously overnight. Once the reaction was complete according to
LCMS, the reactionmixture was diluted with water (3 mL) and the
aqueous layer was extracted with chloroform (2  3 mL). The
organic fractions were discarded and the remaining aqueous
solution was lyophilised to give the title compound as a pale red
amorphous solid (35 mg, 70%). m/z HRMS (ESI, negative mode)
calcd for C69H96Gd3N16O27S: 695.1369 M
3, found 695.1346
(complex pattern due to Gd isotopes; the predicted and observed
isotopic distributions were identical, see ESI†).
[Gd-DOTA]3-N3 15. A solution of 14 (6.1 mg, 0.003 mmol) in
H2O (169 mL) was dissolved in carbonate buﬀer (400 mM, pH
9.4, 134 mL) before a solution of 3-azidopropylamine (1.43 mL,
0.014mmol) in DMSO (33 mL) was added. The reaction was spun
(Stuart rotator) at room temperature for 2 h, then loaded onto
a size exclusion chromatography (LH20) column, and the
product was eluted with H2O. The puried product was
lyophilised to give the title compound as an oﬀ-white solid (5
mg, 76%). m/z HRMS (ESI, negative mode) calcd for C69H96-
Gd3N16O27S: 728.4955 M
3, found 728.4938 (complex pattern
due to Gd isotopes; the predicted and observed isotopic distri-
butions were identical, see ESI†).Bioconjugation reactions
Labelling of lysozyme with [Gd-DOTA]3-ITC 14. Hen egg
white lysozyme at 71 mM in 0.1 M Na2CO3 (pH was not adjusted)
was incubated at 25 C with a 3-fold molar excess of [Gd-
DOTA]3-ITC 14 for 18 h. For SDS-PAGE analysis, reactions wereThis journal is © The Royal Society of Chemistry 2015quenched by addition of one volume of 3 SDS-PAGE loading
buﬀer (containing Tris buﬀer) and one volume of 150 mM DTT
prior to heating to 100 C for 5 minutes and analysis by SDS-
PAGE and HRMS.
Site-specic labelling of Adhiron15C with [Gd-DOTA]3-mal-
eimide 13. The following stock solutions were prepared: [Gd-
DOTA]3-maleimide 13 (10 mM in H2O); Adhiron15C (110 mM in
elution buﬀer: 50 mM NaH2PO4, 500 mM NaCl, 300 mM imid-
azole, 10% glycerol, pH 7.4); tris(2-carboxyethyl)phosphine
(TCEP; 50 mM in water). A solution of Adhiron15C (22.8 mL,
2.5 nmol), 13 (6 mL, 60 nmol) and TCEP (1.2 mL, 60 nmol) were
mixed together and incubated at room temperature. Aer 3 h,
a further aliquot of 13 solution (4 mL, 40 nmol) was added and
the incubation continued for another 3 h. The reaction mixture
was analysed by SDS-PAGE and HRMS.
Two-step site-specic labelling of Adhiron15C with [Gd-
DOTA]3-azide 15. A sample of Adhiron15C in elution buﬀer was
dialysed (2 1 : 1000) into labelling buﬀer (PBS containing 20%
glycerol and 0.05% Tween-20; pH 7.4) to give a protein solution
of 57 mM. 6.1 mL of this solution (0.35 mmol) was treated with
TCEP in H2O (50 mM; 350 mL; 17.5 mmol), labelling buﬀer (185
mL) and DBCO-Mal in DMSO (20 mM; 350 mL, 7 mmol) to give
a nal protein concentration of 50 mM. The reaction was rocked
for 6 hours and monitored by mass spectrometry. Upon
completion, the material was passed through a buﬀer exchange
column (PD-10, GE Healthcare) according to manufacturer's
instructions, eluting 0.5 mL fractions with labelling buﬀer.
Fractions containing protein were identied by BioRad col-
ourimetric assay and pooled. The protein was then concen-
trated to 89 mMby spin concentrator (3 kDa cut-oﬀ), analysed by
HRMS, and used immediately in the next step (or ash frozen
and stored at 80 C if required).
2 mL of this Adhiron15C-DBCO solution (0.17 mmol) was
treated with [Gd-DOTA]3-azide 15 (2 mM in H2O; 175 mL; 0.35
mmol) and the solution was rocked for 6 hours. Upon comple-
tion, thematerial was passed through a buﬀer exchange column
(PD-10, GE Healthcare) according to manufacturer's instruc-
tions, eluting 0.5 mL fractions with labelling buﬀer. Fractions
containing protein were identied by BioRad colourimetric
assay and pooled. Adhiron15C-DBCO-[Gd-DOTA]3 was concen-
trated to 323 mM by spin concentrator (3 kDa cut-oﬀ), analysed
by SDS-PAGE and HRMS, ash frozen and stored at 80 C.Acknowledgements
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